On June 25, MSD China WeChat official account announced that its PD-1 inhibitor Pabolizumab (trade name: Kereida®) had been approved by the National Drug Administration (NMPA) of China to combine trastuzumab, fluorouracil and platinum drugs for first-line treatment of locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma patients with tumor expression of PD-L1 (CPS ≥ 1), which was fully verified by detection and evaluation. The approval of this new indication is based on data from the global phase III clinical trial KEYNOTE-811.